Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions

Source: Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types
Listen to John L. Marshall, MD; Jamie E. Chaft, MD; and Scot Niglio, MD, answer audience questions from a live CCO Webinar on biomarker testing and the impact on immunotherapy treatment for diverse solid tumors including the latest on PD-L1, dMMR/MSI-high, tumor mutation burden, and other emerging biomarkers.
John L. Marshall, MD
Program Director
Jamie E. Chaft, MD
Scot Niglio, MD
Released: August 10, 2020

In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:

  • Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)
  • Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibition
  • Neoadjuvant treatment with immune checkpoint inhibitors
  • Financial considerations when selecting chemotherapy vs immuno-oncology

Content based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.

Link to full program: https://www.clinicaloptions.com/oncology/programs/biomarkers2020

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Program Director

John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho and salary from Caris and Indivumed.

Faculty

Jamie E. Chaft, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Jamie E. Chaft, MD, has disclosed that she has received consulting fees and funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.
Scot Niglio, MD

Medical Oncologist
Bethesda, Maryland

Scot Niglio, MD, has disclosed that his spouse/partner has received a salary from Stemcell Technologies.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

Download this brief slideset on the rationale for using immunotherapy in the treatment of ES-SCLC, from Clinical Care Options (CCO)

Mark A. Socinski, MD Released: December 1, 2020

Download this brief slideset for a review of the latest clinical data informing the optimal use of immunotherapy for treatment-naive ES-SCLC, from Clinical Care Options (CCO)

Mark A. Socinski, MD Released: December 1, 2020

Download this brief slideset on best practices for treating LS-SCLC, from Clinical Care Options (CCO)

person default Benjamin Levy, MD Released: December 1, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue